# Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome

Study · id `cardio:ct-nct01739400` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01739400](<https://clinicaltrials.gov/study/NCT01739400>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01739400

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 217 participants.

## Technical summary

Registry record NCT01739400. Allocation not applicable; no masking; primary purpose treatment. Start 2013-09-10 (actual); primary completion 2018-01-12 (actual). Results posted on 2019-04-16.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 217 participants (enrolled count; ClinicalTrials.gov record NCT01739400, source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)
- Started: 2013-09-10 (actual) (ClinicalTrials.gov record NCT01739400, source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)
- Primary completion: 2018-01-12 (actual) (ClinicalTrials.gov record NCT01739400, source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)
- Completion: 2018-01-12 (actual) (ClinicalTrials.gov record NCT01739400, source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)
- Results first posted: 2019-04-16 (ClinicalTrials.gov record NCT01739400, source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)
- Countries: United States; Austria; Bulgaria; Chile; China; France; Germany; Greece; Malaysia; Mexico; Philippines; Poland; Portugal; Romania; Russia; Serbia; Spain; United Kingdom; Vietnam (ClinicalTrials.gov record NCT01739400, source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01739400-2019-04-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome
- Acronym: MAESTRO-OL
- Condition: Pulmonary Arterial Hypertension
- Intervention (Drug): Macitentan 10 mg tablet, once daily.
- Lead sponsor: Actelion
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Pulmonary arterial hypertension (`cardio:pulmonary-arterial-hypertension`)
- Registry condition terms include this condition: Pulmonary hypertension (`cardio:pulmonary-hypertension`)
- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Actelion (`cardio:org-actelion`)

## Provenance

Content hash: 2fef3bda5957b8ffa52c1122dc5a89d8c002754fdd560f058d7052801edb9f6c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
